Costs associated with persistent allergic rhinitis are reduced by levocetirizine

Bousquet, Jean; Demarteau, Nadia; Mullol, Joaquim; Marle, M. Elske van den Akker-van; Ganse, Éric Van; Bachert, Claus

doi:10.1111/j.1398-9995.2005.00820.x

Cited by 66 publications

(60 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Improvement in work/school productivity and daily activity measured by the WPAI-AS was significantly increased with DL compared with placebo. Other studies have found an effect on work productivity [34], but there was no objective assessment. DL treatment significantly reduced work absenteeism and presenteeism associated with symptoms of allergic rhinitis (IAR and PER).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA<sup>2</sup>LEN Study

Bousquet

Bachert²,

Canonica³

et al. 2010

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines proposed a classification for allergic rhinitis based on the duration of symptoms (intermittent or persistent) rather than on the time of allergen exposure (seasonal or perennial). There had been no placebo-controlled, randomized, clinical trial of desloratadine (DL) in patients with persistent allergic rhinitis to date. Objectives: To assess the efficacy and safety of DL in patients with persistent allergic rhinitis based on the ARIA classification. Methods: Patients 12 years of age and older with persistent allergic rhinitis were assessed over 85 days of treatment with DL 5 mg once daily (n = 360) or placebo (n = 356). The primary endpoint was the AM/PM reflective total 5-symptom score (T5SS) averaged over days 1–29. Secondary endpoints included AM/PM instantaneous T5SS and individual symptoms, therapeutic response, symptom severity assessed by a visual analogue scale and quality of life. Results: The mean reduction in AM/PM reflective T5SS was significantly greater with DL than placebo over days 1–29 (–3.76 vs. –2.87, p < 0.001) and on each individual day (p < 0.05). The mean AM instantaneous T5SS was significantly reduced with DL compared with placebo as early as day 2 (–1.90 vs. –1.46; p < 0.001). The therapeutic response and improvement in quality of life were significantly greater with DL than placebo (p < 0.001 for each). The frequency of treatment-related adverse events was low and similar between DL (10.0%) and placebo (8.4%). Conclusions: This study showed DL to be effective and safe in the treatment of persistent allergic rhinitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA<sup>2</sup>LEN Study

Bousquet

Bachert²,

Canonica³

et al. 2010

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…It is commonly accepted that allergic rhinitis impairs work (10,84,113,1114,1115). It induces work absenteeism as well as a reduction in work productivity and presenteeism.…”

Section: Work Impairmentmentioning

confidence: 99%

“…Direct medical cost parameters (medications, doctor visits and hospitalizations) and time-lost parameters [work days and Usual Daily Activities (UDA)] related to PER and its co-morbidities were measured in a prospective 6-month study comparing levocetirizine and placebo in patients with moderate/severe PER (1115). From a societal perspective, the total cost of PER without long-term treatment was estimated at €355 per patient per month.…”

Section: The Costs Of Illness For Rhinitis and Its Co-morbiditiesmentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

Self Cite

3,859

1,761

View full text Add to dashboard Cite

“…Very few studies have assessed the costs of managing allergic rhinitis in Europe (13). However, in one study, the direct medical cost of treating the disease in France was estimated to be Euro 510 million in 1997 (14), which is significantly higher than the costs for treating diseases such as epilepsy and colorectal cancer (13). Interestingly, in the US alone, it accounts for 3.5 million lost workdays and 2 million lost school-days each year (3).…”

Section: Allergic Rhinitismentioning

confidence: 99%

Ebastine in allergic rhinitis and chronic idiopathic urticaria

Sastre

2008

Allergy

View full text Add to dashboard Cite

Histamine is a key mediator in the development of allergy symptoms, and oral H1‐antihistamines are among the most widely used treatments for symptomatic relief in conditions such as allergic rhinitis and chronic urticaria. Ebastine is a second‐generation antihistamine which has been shown to be an effective treatment for both seasonal and perennial allergic rhinitis. In controlled clinical trials in adult and adolescent patients with allergic rhinitis, ebastine 10 mg once‐daily improved symptoms to a significantly greater extent than placebo and to a similar extent as loratadine 10 mg and cetirizine 10 mg (both once‐daily), while ebastine 20 mg proved to be more effective than these two comparator antihistamines. In addition, ebastine was significantly more effective than placebo at relieving the symptoms of chronic idiopathic urticaria. Ebastine provides efficacy throughout the 24‐h dosing interval with once‐daily administration and clinical benefit is seen from the first day of treatment. Small studies have found beneficial effects for ebastine in patients with other disorders, including cold urticaria, dermographic urticaria, atopic asthma, mosquito bites and (in combination with pseudoephedrine) the common cold. In addition to the regular ebastine tablet, a fast‐dissolving tablet (FDT) formulation, which disintegrates in the mouth without the aid of a drink, is also available. It has been shown to be bioequivalent to the regular tablet, and to be significantly more effective than desloratadine at reducing histamine‐induced cutaneous wheals. A number of patient surveys demonstrated that the majority of individuals who tried the fast‐dissolving formulation reported it to be convenient for use, fast‐acting and preferred it to their previous antihistamine medication. Perhaps most importantly, a large proportion of patients indicated that they would prefer to use this new formulation in the future. Ebastine has a rapid onset of action and it can be administered once‐daily, with or without food. Dose modifications are not needed in elderly patients, or in those with renal or mild to moderate hepatic impairment. Ebastine is generally well‐tolerated, and clinical studies showed that at usual therapeutic doses of 10 and 20 mg once‐daily, it had no clinically relevant adverse effects on cognitive function and psychomotor performance or on cardiovascular function. In conclusion, ebastine is an effective and generally well‐tolerated treatment for allergic rhinitis and chronic idiopathic urticaria. In addition to the regular tablet formulation, ebastine is available as a FDT, providing a treatment option that is particularly convenient for patients.

show abstract

Costs associated with persistent allergic rhinitis are reduced by levocetirizine

Abstract: The cost of persistent allergic rhinitis is substantial. Treatment with levocetirizine reduces the cost of persistent allergic rhinitis and its comorbidities to the society by 152.93/patient/month while improving symptoms and health-related quality of life.

Cited by 66 publications

References 23 publications

Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA<sup>2</sup>LEN Study

Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA<sup>2</sup>LEN Study

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Ebastine in allergic rhinitis and chronic idiopathic urticaria

Contact Info

Product

Resources

About